Measurement validation of treatment planning for a MR-Linac

Xinfeng Chen | Eric S. Paulson | Ergun Ahunbay | Aydin Sanli | Slade Klawikowski | X. Allen Li

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

Author to whom correspondence should be addressed. X. Allen Li
E-mail: ali@mcw.edu; Telephone: 414-805-4362; Fax: 414-805-4369.

Funding information
MCW Cancer Frotsch and Meinerz Foundations; Elekta AB

Abstract

Purpose: The magnetic field can cause a nonnegligible dosimetric effect in an MR-Linac system. This effect should be accurately accounted for by the beam models in treatment planning systems (TPS). The purpose of the study was to verify the beam model and the entire treatment planning and delivery process for a 1.5 T MR-Linac based on comprehensive dosimetric measurements and end-to-end tests.

Material and methods: Dosimetry measurements and end-to-end tests were performed on a preclinical MR-Linac (Elekta AB) using a multitude of detectors and were compared to the corresponding beam model calculations from the TPS for the MR-Linac. Measurement devices included ion chambers (IC), diamond detector, radiochromic film, and MR-compatible ion chamber array and diode array. The dose in inhomogeneous phantom was also verified. The end-to-end tests include the generation, delivery, and comparison of 3D and IMRT plan with measurement.

Results: For the depth dose measurements with Farmer IC, micro IC and diamond detector, the absolute difference between most measurement points and beam model calculation beyond the buildup region were <1%, at most 2% for a few measurement points. For the beam profile measurements, the absolute differences were no more than 1% outside the penumbra region and no more than 2.5% inside the penumbra region. Results of end-to-end tests demonstrated that three 3D static plans with single 5 x 10 cm² fields (at gantry angle 0°, 90° and 270°) and two IMRT plans successfully passed gamma analysis with clinical criteria. The dose difference in the inhomogeneous phantom between the calculation and measurement was within 1.0%.

Conclusions: Both relative and absolute dosimetry measurements agreed well with the TPS calculation, indicating that the beam model for MR-Linac properly accounts for the magnetic field effect. The end-to-end tests verified the entire treatment planning process.

KEY WORDS
beam model verification, electron returning effect, MR-guided RT, MR-Linac, treatment planning system
1 INTRODUCTION

Integrated MRI guided radiation therapy (MRgRT) systems are emerging radiation therapy (RT) techniques that combine a MR-scanner with either a linear accelerator (MR-Linac)\(^1\)–\(^3\) or Co-60 teletherapy system.\(^4\) The main magnetic field of the MRI is oriented either longitudinal or transverse to the central axis of the radiation beam. Owing to MRI’s capability to provide excellent soft-tissue contrast images and biological/functional information, these systems are expected to enable adaptive RT and provide real-time, high quality image guidance during delivery with the potential to significantly improve RT outcomes. However, the presence of the magnetic field (ranging from 0.35 to 1.5 T) has nonnegligible dosimetric effects in patients due to the Lorenz deflection effect of the secondary electrons from the primary photon beam. The responses of the radiation dose measurement devices are also affected by the presence of the magnetic field.

The dosimetric effect of a transverse magnetic field (TMF) in phantom and patients has been studied extensively.\(^5\)–\(^12\) Compared to conventional external beam RT without magnetic field, the magnetic field can generally lead to an altered buildup depth, and a larger, slightly shifted (asymmetric) penumbra arising from tilting of the dose kernel.\(^5\) The dose deposited at tissue-air interfaces can increase due to the electron returning effect (ERE),\(^6\) which can also be affected by the surface orientation where the photon beam enters or exits.\(^8\) The dosimetric response of QA devices\(^17\)–\(^27\) (especially the detectors used for beam calibration) in magnetic fields have also been studied, focusing mainly on the absolute dose response of the detectors. The effect of the magnetic field on the detectors is demonstrated\(^26\) not only through the trajectory path deflection of the secondary electrons in the medium surrounding and inside the volume of the gas-filled or solid detector, but also through the change of the intrinsic properties of detectors such as charge carrier versus lattice defect recombination, polarity effect, etc. For the ionization chamber, however, when the field size is sufficiently larger than the detector’s diameter, an additional magnetic field and beam quality correction factor\(^18\) can be applied to the original calibration coefficient, obtained without the magnetic field, to obtain the correct absolute dose calibration in the presence of the magnetic field. The effective point of measurement (EPOM) of the ionization chamber\(^27\) is shifted not only in the beam direction but also laterally, perpendicular to both the beam and the magnetic field direction. According to O’Brien et al.\(^27\), the measured lateral shift in the dose distribution was independent of depth and field size from 2 × 2 cm\(^2\) to 10 × 10 cm\(^2\). The depth of maximum dose had little dependence on field size in the presence of the magnetic field. The output factors measured at the point of the peak intensity in the cross plane profile are more consistent than those measured at the central axis (CAX).

The MR-Linac system developed by Elekta AB (Stockholm, Sweden) in cooperation with Philips Healthcare (Best, Netherlands) consists of an Elekta linear accelerator with a nominal 7MV flattening filter-free photon beam (160-leaf MLC oriented in fixed superior-inferior direction), and a Philips 1.5 T integrated wide-bore MRI scanner. With this system, the magnetic field is oriented transverse to the irradiation field. To match the MR-Linac, the treatment planning system (TPS) must incorporate the effects of magnetic fields. A prototype TPS (Monaco research version v5.0.19.03, provided by Elekta AB) developed for the MR-Linac employs a graphics processing unit (GPU)-based Monte Carlo dose calculation algorithm\(^28\) and considers a uniform magnetic field with strength and orientation as input.\(^29\) The main purposes of this study were to: (a) validate the beam models in the TPS by comparing the model predictions with comprehensive dosimetric measurement data from the MR-Linac and (b) verify the performance of the entire planning and delivery process by carrying out a series of end-to-end tests on the MR-Linac.

2 MATERIALS AND METHODS

All the measurement data were collected on a preclinical MR-Linac (Elekta AB) installed at Froedtert Hospital and Medical College of Wisconsin Cancer Center. The MR-Linac is equipped with an electronic portal imaging device (EPID), which was used to localize dosimeters and phantoms spatially since there is no laser system currently installed in the MR-Linac environment. The image pixel size for EPID is approximately 0.2 mm. The uncertainty of the alignment of the dosimeters and phantoms based on EPID is no more than 1 mm. The devices and measurement setups are described in details in Sections 2.1–2.4 and 2.6.2.2.

The dosimetric data in the same conditions of the measurements were generated with the prototype Monaco TPS using the beam model provided by the vendor. For the end-to-end tests, a variety of dosimetric plans including three 3D static plans with single rectangular fields and two IMRT patient and QA plans were generated using the TPS and were delivered on the MR-Linac. The details of the plans are described in Sections 2.5.2.1 and 2.6.2.2.

2.1 Water tank measurements

Most relative and absolute dosimetry measurements were performed using an in-house built water tank with a hand-cranked gear mechanism to position the dosimetry detector at a required depth with increments of 0.1 mm. The volume of the water tank was 52.3 cm (X) × 42 cm (Y) × 24 cm (Z), where the X direction is oriented from patient left to right; Y is oriented patient inferior to superior; and Z is oriented from patient anterior to posterior. The hand-cranked gear can slide in x direction with an attached ruler to adjust the X position for cross-plan beam profile measurements. The table coordinates were used to determine the Y positions for in-plan beam profile measurement. The distance from water surface to the couch top was 26.6 cm and the distance from the couch top to the machine isocenter is 14.3 cm, which results in an SSD of 131.2 cm since the SAD of the MR-Linac is 143.5 cm.

The detectors used for water tank measurements include: PTW TN 30013 Farmer ion chamber (IC) (S/N: 9003; nominal sensitive
volume is 0.6 cm³); PTW FREIBEG N31014 micro IC (previously N31006, S/N: 0177; nominal sensitive volume is 0.015 cm³) and PTW TN 60019 microdiamond detector (S/N: 122257, active volume: 0.004 mm³). For the Farmer IC measurement, the long axis of the chamber was oriented along the longitudinal direction of the couch and parallel to the direction of the magnetic field. The measurements with micro chamber and diamond detector were obtained with the long axis of the detector parallel to the beam direction at gantry 0°, thus perpendicular to the magnetic field. The alignment of the center of the detector with the radiation center was confirmed with the portal imager at gantry angles 0°, 90°, 180°, and 270° and the position uncertainty was less than 1.0 mm.

Considering the spatial limits between the isocenter and couch top and the geometry of the water tank, all percent depth dose (PDD) and beam profile measurements were performed at SSD = 131.2 cm, rather than 143.5 cm (the MR Linac isocenter). The total backscatter was 12.3 cm of water plus 1 cm of acrylic (bottom of the water tank) and the couch top when the detector located at the isocenter.

All measurements were performed with the gantry at 0° (i.e., perpendicular to the water surface). The field sizes and depth for all the PDD and beam profile measurements are listed in Tables 1 and 2. The field size is defined at the isocenter.

2.B | Radiochromic film measurements

Radiochromic film (GAFchromic EBT-3) was used as a secondary validation of measurements obtained from other detectors, particularly for small field sizes, for example, in the range of 1 × 1 to 5 × 5 cm². The EBT3 film was sandwiched between slabs of solid water and positioned on the couch so that the film was oriented coronally at depth 1.5 cm with SSD 131.2 cm. The cross-plane beam profiles were extracted for field size 1 × 1, 2 × 2, 3 × 3, and 5 × 5 cm² using a film processing software (Radiological Imaging Technology, Inc).

Table 3 The comparison of the depth of the maximum percent depth dose for different field size between the calculation from the treatment planning systems and measurements with different detectors [Farmer ion chambers (IC), Diamond detector, and the micro IC].

| Field size (cm²) | Beam model | Farmer IC | Diamond | Micro IC |
|-----------------|------------|-----------|---------|---------|
| 10 × 10         | 1.4        | 1.4       | 1.4     | 1.4     |
| 5 × 5           | 1.4        | 1.4       | 1.5     | 1.4     |
| 3 × 3           | 1.3        | 1.3       | 1.2     |         |
| 2 × 2           | 1.1        | 1.1       | 1.2     |         |
| 1 × 1           | 1.0        | 1.1       | 1.0     |         |

**Figure 1.** Percentage depth dose curves measured in liquid water using micro ion chambers (IC), diamond detector, and Farmer IC.
2.C | MR-Compatible 2D ion chamber array measurements

In-plane and cross-plane beam profiles were also measured using an MR-compatible 2D ion chamber array (IC profiler, Sun Nuclear Corporation, Melbourne, FL) for field sizes $5 \times 5$, $10 \times 10$, $15 \times 15$, $20 \times 20$, and $30 \times 22$ cm$^2$ with gantry $0^\circ$ at depths of 1.5, 5.0, 10.0, and 15.0 cm. The SSD was 131.2 cm, which is the same as the water tank measurements for the convenience of comparison. There was a 1 cm inherent water equivalent build up within the IC profiler itself.

2.D | Reference dose verification

Reference dose verification was performed in liquid water using an ion chamber based on O’Brien et al.’s formalism$^{18}$ for reference dosimetry in magnetic fields. Given the difficulties to setup the standard TG-51$^{30}$ reference condition with the MR-Linac geometry, the formalism of Alfonso et al.$^{31}$ for small and nonstandard beams was adopted and corrected for the purpose of reference dose verification. In Alfonso’s formalism, a set of machine-specific-reference (msr) conditions (e.g., smaller field size, different phantom shape, and material) were introduced. The absolute dose to water in an applied magnetic field $B$ for the machine-specific reference field size $f_{msr}$ can be determined using Eq. (1)$^{18}$:

$$D_B^{f_{msr} w Q_{msr}} = M_B^{f_{msr} w Q_{msr}} N_B^{f_{msr} w Q_{msr}} k_B^{f_{msr} w Q_{msr}}$$

where $k_B^{f_{msr} w Q_{msr}}$ is a correction factor to account for the magnetic field effect on the dose response of the ion chamber. For our reference dose verification, $k_{Q_0}$ was determined based on TPR$_{20,10}$ measurement according to the TRS-398 code–of-practice.$^{32}$ The field size of $10 \times 10$ cm$^2$ (defined at isocenter) was used for the calibration. Thus:

$$k_{Q_0}^{f_{msr} w Q_{msr}} = 1.$$

The $k_{Q_0}^{f_{msr} w Q_{msr}}$ was chosen with reference to Table 3 of O’Brien et al.’s formalism.$^{18}$ The measurement was performed at

![Fig. 2. Measured and calculated percent depth doses (PDDs) for different field sizes. Differences between measured and calculated PDD are plotted below each PDD.](image-url)
SSD = 133.5 cm and the ion chamber was placed at a depth of 10 cm. The tissue maximum ratio (TMR) at depth 10 cm was also measured to convert the dose at the point of measurement to the reference point which was chosen to be d_{max} at SAD to mimic the other Linacs in our clinic. An ADCL-calibrated local standard PTW 30013 water-proof Farmer chamber and Keithley electrometer (#35614) were used for the measurement.

2.E | Data calculated from beam models

The dosimetric data in the same conditions as in the measurements described above were generated using the prototype Monaco TPS with the existing MR-Linac beam model (7.0FFF + cryostat) using a calculation grid of 3 mm × 3 mm × 3 mm. The data were extracted from 3D plans of single beams irradiating onto a rectangular water phantom similar to the water tank. The PDDs along the CAX and the beam profiles for each field size at corresponding depths were extracted from the corresponding 3D dose distributions.

2.F | End-to-end tests with an MR compatible 3D diode array

For the end-to-end tests, three single-beam 3D plans based on CT data of an MR-compatible cylindrical 3D diode array (ArcCheck,

![Image of cross-plane and in-plane beam profiles measured with micro ion chambers for different field sizes at depth of 1.5 cm along with the beam model calculations.]

**Table 4** The deviations (unit: cm) of the center of the cross-plane profiles from the central axis for different field sizes (1 × 1, 2 × 2, 3 × 3, 5 × 5 and 10 × 10 cm²) at different depth (1.5, 5.0, 10.0 and 15.0 cm). (Meas.: Measurement; B.M.: Beam Model).

| Field size/depth (cm) | 1 × 1 | 2 × 2 | 3 × 3 | 5 × 5 | 10 × 10 |
|-----------------------|-------|-------|-------|-------|--------|
| 1.50                  | Meas. | 0.10  | 0.09  | 0.14  | 0.13   | –   |
|                       | B.M.  | 0.11  | 0.13  | 0.14  | 0.14   | 0.14 |
| 5.00                  | Meas. | 0.12  | 0.13  | 0.15  | 0.15   | –   |
|                       | B.M.  | 0.12  | 0.14  | 0.14  | 0.15   | 0.15 |
| 10.00                 | Meas. | 0.17  | 0.17  | 0.20  | 0.16   | –   |
|                       | B.M.  | 0.13  | 0.15  | 0.15  | 0.16   | 0.16 |
| 15.00                 | Meas. | 0.19  | 0.20  | 0.24  | 0.20   | –   |
|                       | B.M.  | 0.14  | 0.16  | 0.16  | 0.17   | 0.17 |

![Image of in-plane and cross-plane beam profiles measured with diamond detector for different field sizes and depths in liquid water.]

**Fig. 3.** Cross-plane beam profiles measured with diamond detector for different field sizes and depths in liquid water.

**Fig. 4.** In-plane and cross-plane beam profiles measured with micro ion chambers for different field sizes at depth of 1.5 cm along with the beam model calculations.
Model 1220-MR, Sun Nuclear Corporation, Melbourne, FL) were generated for a rectangular field of $5 \times 10 \text{ cm}^2$ at gantry angles 0°, 90°, and 270°, respectively. In addition, two realistic step-and-shoot IMRT plans were generated based on two sample patient CT sets of pancreas cancer using commonly used dose-volume constraints. The corresponding QA plans for the IMRT plans were created based on the ArcCheck CT set following the clinical procedure. The 3D plans and IMRT QA plans were generated on ArcCheck such that the position of the isocenter in the TPS matched the isocenter of the MR-Linac. All these plans were delivered to the ArcCheck on the MR-Linac following the workflow built in the MR-Linac. The ArcCheck was aligned manually by comparing a serial of measured dose maps of a $5 \times 10 \text{ cm}^2$ beam at gantry angles of 0°, 90°, and 270° with the corresponding dose distributions generated with the TPS. The dose calibration for the ArcCheck was performed with MR-Linac and the Diode array calibration was performed using a 6 MV, $10 \times 10 \text{ cm}^2$ photon beam from a conventional linac (Versa-HD, Elekta AB, Stockholm, Sweden). The measured dose maps from the diode array of ArcCheck were compared with the dose distributions from the TPS with a commonly used gamma analysis (3%/3 mm with 5% threshold).

2.G | Dose verification in inhomogeneous phantom

To verify the TPS dose calculation accuracy in inhomogeneous tissue, we performed dose measurements in a homemade phantom using an MR-compatible ion chamber (A26MR, Standard Imaging) with a sensitive volume of 0.016 cm³. The inhomogeneous phantom was composited of nine slabs of different relative electron densities (rED) similar to lung, soft tissue, and bones. The dose distribution of

---

**Figure 5.** Measured and modeled cross-plane beam profiles across multiple field sizes at depth = 1.5 cm. Min($D/R$)(mm/%): The minimum of the distance (mm) difference and relative dose (%) difference between measurements and beam model.
a single beam with $10 \times 10$ cm$^2$ field size and 200 MU at gantry 0° from the MR-Linac was calculated in the TPS on the CT of the phantom in SAD setup. The calculated mean dose in the sensitive volume of the ion chamber located at the depth of 11 and 0.3 cm off central axis in the phantom was extracted from the TPS and was compared with the measurement.

3 | DATA ANALYSIS AND RESULTS

3.A | Percentage depth dose

Figure 1 displays PDDs measured with Farmer IC, diamond detector, and micro IC. Since the PTW Farmer ion chamber has the largest effective detector volume, it was used for dosimetry measurements of the larger field sizes ($\geq 5 \times 5$ cm$^2$). With much smaller sensitive volume, the diamond detector and micro IC were used for small field measurements ($< 5 \times 5$ cm$^2$). To check the consistency between the various detectors, the PDD for field sizes of $5 \times 5$ and $10 \times 10$ cm$^2$ were also measured with both diamond detector and micro IC.

The measured PDDs were compared against those calculated from the beam model in the TPS for field sizes $\leq 10 \times 10$ cm$^2$ in Fig. 2. The differences between the measured and calculated PDDs are also shown in Fig. 2. Beyond the buildup region, the PDDs measured with all detectors agreed well with the beam model. The absolute difference for most measurement points was $< 1\%$ (range $\pm 2\%$). In general, the measurements with the diamond detector lead to smaller deviations from those by the beam models as compared to those by the micro IC. The depth of maximum (i.e., $d_{\text{max}}$) decreases with decreasing field size, from approximately 1.4 cm for field size $10 \times 10$ cm$^2$ to 1.0 cm for field size $1 \times 1$ cm$^2$, as shown in both measured and calculated data in Table 3.

3.B | Cross-plane and in-plane beam profiles

Since the magnetic field affects dosimetry mostly in transverse planes, the majority of the data were collected in the cross-plane direction. The large field cross-plane beam profiles ($\geq 5 \times 5$ cm$^2$) were measured with the Farmer IC and IC profiLe$^{\text{TM}}$. Those for small field sizes, for example, $1 \times 1$, $2 \times 2$, $3 \times 3$, and $5 \times 5$ cm$^2$, were measured with diamond detector, micro IC, and radiochromic film. For the consistency check, the cross-plane beam profiles for field size $10 \times 10$ cm$^2$ was also measured with both the diamond detector and micro IC. Due to the geometrical limitations of the water tank for larger field sizes ($\geq 10 \times 10$ cm$^2$), only a portion of the cross-plane beam profiles could be obtained. Figure 3 displays cross-plane beam profiles measured with the diamond detector at different
depths (1.5, 5.0, 10.0, and 15.0 cm) for different field sizes. The deviations of the center of the cross-plane profiles from the CAX were extracted and compared to the beam model calculation for different depth and field size as shown in Table 4. The in-plane beam profiles for field sizes: 1 × 1, 2 × 2, 3 × 3, 5 × 5, and 10 × 10 cm² were measured with the micro IC. These in-plane measurements at depth 1.5 cm along with the cross-plane profiles measured with the same chamber are shown in Fig. 4.

FIG. 7. A comparison of measured and calculated dose maps for an IMRT plan. Top left: Dose distribution of the QA plan on ArcCheck CT; Top right: Dose distributions on the patient CT; Bottom: Comparisons of doses measured (ArcCheck) and calculated (Plan) as analyzed with SNC Patient™.
Cross-plane beam-profile measurements at depth 1.5 cm with different detectors for field sizes $1 \times 1$, $2 \times 2$, $3 \times 3$, $5 \times 5$, and $10 \times 10 \text{cm}^2$ are compared with the beam model calculations in Fig. 5. The minimum of the distance (mm) difference and relative dose (%) difference between measured and modeled profiles are plotted in the same figure. In general, the beam profiles measured with different detectors agree well with those from the beam models, with no more than 1% difference in the regions outside the penumbra and no more than 2% for most regions within the primary beam, except within the penumbra regions. In the penumbra regions, the agreement is within 1.0 mm for most data points of all field sizes studied. The film and diamond detector measurements generally display sharper falloff in penumbra regions compared to those from the beam model and micro IC measurements. The beam model correctly models ERE by using tilted dose kernels. It is clear that there are lateral shifts (i.e., asymmetry) of the cross-plane beam profiles to the direction of patient-left. The shift of the center of the cross-plane profile increases slightly with the depth and field size, but the measured differences of the shift are within 1 mm compared to 0.5 mm calculated with the beam model (see Table 4). As expected, no lateral shifts in in-plane beam profiles were observed and the dose distribution is symmetric and peaks at CAX for both measured and calculated data.

3.C | Reference dose verification

Based on the type of ion chamber and its orientation with respect to the irradiation and magnetic fields, a $k_\text{eq}$ of 0.994 was used for the reference dose verification.\cite{18} The absolute dose at the measurement point was determined to be 87.66 cGy per 100 MU. A reference dose of 111.8 cGy/100 MU was obtained at the depth of maximum dose with SAD setup ($d_{\text{max}}$, SAD) when a TMR of 0.784 was used to convert the dose at the measurement point to the reference point.

3.D | End-to-end tests

The three single-beam plans with a $5 \times 10 \text{cm}^2$ field at gantry 0°, 90°, and 270° were delivered to the ArcCheck and the measured dose was compared with the TPS calculations. Figure 6 displays dose comparison between a planned and ArcCheck measured $5 \times 10 \text{cm}^2$ rectangular field at gantry 0° using SNC Patient™ software. The test beams at three gantry angles all passed with more than 99% in absolute mode using gamma analysis and clinic criteria. These excellent agreements indicate that the ArcCheck was aligned properly.

The two step and shoot IMRT QA plans, with 6 and 5 beam angles, respectively, were delivered to the ArcCheck on MR-Linac. The workflow for the IMRT delivery was: The IMRT plan generated with TPS is exported to the Record-and-Verify system (MOSAIQ, Elekta AB) and is then imported into Treatment Service Manager (TSM); the TSM communicates with the MR-Linac console and controls the delivery of each beam to the ArcCheck. The measured dose maps were compared with the plan dose maps using SNC Patient™ software and the QA plans were successfully passed with 96.5% and 97.7% using gamma analysis with clinical criteria. Figure 7 presents the analysis of comparisons between the measured and planned dose.
distributions for one of the IMRT plan, along with the isodose lines of the patient and QA plans on patient and ArcCheck CTs.

3.E Dose verification in inhomogeneous phantom

Figure 8 shows the TPS calculated dose distribution on a transverse plane of the inhomogeneous phantom. The ERE is obvious at the plane of the inhomogeneous phantom. The measurements performed during the deliveries of these plans on the MR-linac passed absolute dosimetric criteria commonly used in the clinic.

ACKNOWLEDGMENT

The research is partially supported by MCW Cancer Fotsch and Meinerz Foundations and by Elekta AB, Stockholm, Sweden. Inputs from Diane Schott and Phil Prior are appreciated.

CONFLICTS OF INTEREST

The authors declare there is no conflict of interest.

REFERENCES

1. Lagendijk JJW, Raaymakers BW, van Vulpen M. The magnetic resonance imaging-linac system. Semin Radiat Oncol. 2014;24:207–209.

2. Fallone BG. The rotating bimodal linac-magnetic resonance imaging system. Semin Radiat Oncol. 2014;24:200–202.

3. Keall PJ, Barton M, Crozier S. The Australian magnetic resonance imaging-linac program. Semin Radiat Oncol. 2014;24:203–206.

4. Mutic S, Dempsey JF. The viewray system: Magnetic resonance-guided and controlled radiotherapy. Semin Radiat Oncol. 2014;24:196–199.

5. Raaymakers BW, Raaijmakers AE, Kotte ANTJ, Jette D, Lagendijk JJW. Integrating a MRI scanner with a 6 MV radiotherapy accelerator: dose deposition in a transverse magnetic field. Phys Med Biol. 2004;49:4109.

6. Raaijmakers AE, Raaymakers BW, Lagendijk JJW. Experimental verification of magnetic field dose effects for the MRI-accelerator. Phys Med Biol. 2007;52:4283.

7. Raaijmakers AE, Raaymakers BW, Lagendijk JJW. Integrating a MRI scanner with a 6 MV radiotherapy accelerator: dose increase at tissue-air interfaces in a lateral magnetic field due to returning electrons. Phys Med Biol. 2005;50:1363.

8. Raaijmakers AE, Raaymakers BW, Lagendijk JJW. Experimental verification of magnetic field dose effects for the MRI-accelerator. Phys Med Biol. 2007;52:4283.

9. Raaijmakers AE, Raaymakers BW, Lagendijk JJW. Integrating a MRI scanner with a 6 MV radiotherapy accelerator: impact of the surface orientation on the entrance and exit dose due to the transverse magnetic field. Phys Med Biol. 2007;52:929.

10. Raaijmakers AE, Härdeemark B, Raaymakers BW, Raaijmakers CPJ, Lagendijk JJW. Dose optimization for the MRI-accelerator: IMRT in the presence of a magnetic field. Phys Med Biol. 2007;52:7045.

11. Raaijmakers AE, Raaymakers BW, Lagendijk JJW. Magnetic-field-induced dose effects in MR-guided radiotherapy systems: dependence on the magnetic field strength. Phys Med Biol. 2008;53:909.

12. Oborn BM, Metcalfe PE, Butson MJ, Rosenfeld AB. High resolution entry and exit Monte Carlo dose calculations from a linear accelerator 6 MV beam under the influence of transverse magnetic fields. Med Phys. 2009;36:3549–3559.

13. Bol GH, Lagendijk JJW. Raaymakers BW. Compensating for the impact of non-stationary spherical air cavities on IMRT dose delivery in transverse magnetic fields. Phys Med Biol. 2015;60:755–768.

14. Ullikema S, van der Heide U, Sonke J, Moreau M, van Triest B, Nijkamp J. A 1.5 T transverse magnetic field in radiotherapy of rectal cancer: impact on the dose distribution. Med Phys. 2015;42:7182–7189.

15. Rubinstein AS, Liao T, Melancon AD, et al. Technical note: a Monte Carlo study of magnetic-field-induced radiation dose effects in mice. Med Phys. 2015;42:5510–5516.

16. Yang YM, Geurts M, Smilowitz JB, Sterpin E, Bednarz BP. Monte Carlo simulations of patient dose perturbations in rotational-type
radiotherapy due to a transverse magnetic field: a tomotherapy investigation. Med Phys. 2015;42:715–725.
16. Chen X, Prior P, Chen G, Schultz CJ, Li XA. Technical note: dose effects of 1.5 T transverse magnetic field on tissue interfaces in MRI-guided radiotherapy. Med Phys. 2016;43:4797–4802.
17. O’Brien DJ, Schupp N, Pencea S, Dolan J, Sawakuchi GO. Dosimetry in the presence of strong magnetic fields. J Phys. 2017;847:012055.
18. O’Brien DJ, Roberts DA, Ibbott GS, Sawakuchi GO. Reference dosimetry in magnetic fields: formalism and ionization chamber correction factors. Med Phys. 2016;43:4915–4927.
19. Garrett M, Oborn B, Metcalfe P, Rosenfeld A. Monte Carlo simulation of the dose response of a novel 2D silicon diode array for use in hybrid MRI-LINAC systems. Med Phys. 2015;42:856–865.
20. Reynolds M, Fallone BG, Rathee S. Technical note: response measurement for select radiation detectors in magnetic fields. Med Phys. 2015;42:2837–2840.
21. Reynolds M, Fallone BG, Rathee S. Dose response of selected solid state detectors in applied homogeneous transverse and longitudinal magnetic fields. Med Phys. 2014;41:092103.
22. Smit K, Sjöholm J, Kok JGM, Lagendijk JJW, Raaymakers BW. Relative dosimetry in a 1.5 T magnetic field: an MR-linac compatible prototype scanning water phantom. Phys Med Biol. 2014;59:4099–4109.
23. Reynolds M, Fallone BG, Rathee S. Dose response of selected ion chambers in applied homogeneous transverse and longitudinal magnetic fields. Med Phys. 2013;40:042102.
24. Smit K, van Asselen B, Kok JGM, Aalbers AHJ, Lagendijk JJW, Raaymakers BW. Towards reference dosimetry for the MR-linac: magnetic field correction of the ionization chamber reading. Phys Med Biol. 2013;58:5945–5957.
25. Meijsing I, Raaymakers BW, Raaijmakers AJE, et al. Dosimetry for the MRI accelerator: the impact of a magnetic field on the response of a Farmer NE2571 ionization chamber. Phys Med Biol. 2009;54:2993–3002.
26. Looe HK, Delfs B, Poppinga D, Harder D, Poppe B. Magnetic field influences on the lateral dose response functions of photon-beam detectors: MC study of wall-less water-filled detectors with various densities. Phys Med Biol. 2017;62:5131–5148.
27. O’Brien DJ, Dolan J, Pencea S, Schupp N, Sawakuchi GO. Relative dosimetry with an MR-linac: response of ion chambers, diamond, and diode detectors for off-axis, depth dose, and output factor measurements. Med Phys. 2018;45:884–897.
28. Hissoiny S, Ozell B, Bouchard H, Després P. GPUMCD: a new GPU-oriented Monte Carlo dose calculation platform. Med Phys. 2011;38:754–764.
29. Hissoiny S, Raaijmakers AJE, Ozell B, Després P, Raaymakers BW. Fast dose calculation in magnetic fields with GPUMCD. Phys Med Biol. 2011;56:5119.
30. Almond PR, Biggs PJ, Coursey BM, et al. AAPM’s TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams. Med Phys. 1999;26:1847–1870.
31. Alfonso R, Andreo P, Capote R, et al. A new formalism for reference dosimetry of small and nonstandard fields. Med Phys. 2008;35:5179–5186.
32. IAEA. Absorbed Dose Determination In External Beam Radiotherapy. Vienna: International Atomic Energy Agency; 2000.